Recent papers have addressed critical issues regarding the microstaging of
cutaneous melanoma. They concern the new staging proposal by the American J
oint Committee on Cancer (AJCC), the presentation of new prognostic models
than seem applicable in daily practice, and new immunohistochemical finding
s than demonstrate prognostic information independently of the conventional
major factors. These issues are commented on by the Pathology Committee of
the EORTC Melanoma Group.